Keywords: Bayer, Nexavar, Indian compulsory license, IPAB decision, Natco Pharma

Indian patent appeal board upholds compulsory license on Bayer's Nexavar

Article | 05 March 2013

Print This

After much delay, the verdict into German pharmaceutical major Bayer’s (BAYN: DE) appeal against the grant of a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in